Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2022

View Archived Issues

Synthesis and biological activity of water-soluble sulfonated aurones, including acidoaurone

New isomeric aza-analogues of natural jaspine B: synthesis and in vitro antiproliferative activity

Development of haloperidol analogues as Eis inhibitors to overcome kanamycin resistance in MDR TB

Targeting GNAO1 presents a new therapeutic strategy for heart failure

PTP1B inhibition enhances T-cell and CAR T-cell antitumor immunity

Novel 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as inhibitors of SARS-CoV-2 RdRp

Identification and in vivo evaluation of novel potential P2Y12 receptor PET tracers

Researchers unveil SEC61 targeting as an approach for treating multiple myeloma

Autobahn Therapeutics patents thyroid hormone receptor agonists

Merck Sharp & Dohme presents new SCN10A blockers

AstraZeneca identifies new PARP-1 inhibitors

Roche synthesizes new Mat2A inhibitors

Alchemedicine discovers CK1 and/or TGFBR1 inhibitors

Researchers restore front-line antibiotics' effects

Lantern Pharma expands collaboration with NCI to support progression of LP-184 and LP-284

Immix reports promising response rate with IMX-110 in first-line therapy-resistant STS mouse study

Hemogenyx and Selexis agree to develop cell line for Hemogenyx's CDX bispecific antibody

Modulation of IL-19 regulates DNA damage-induced cytokine production

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.